The Kashi Cardiac Health Panel gives insight into how a patient’s genetic predisposition to cardiac problems can help healthcare providers optimize diagnosis and treatment. Cardiovascular disease is a leading contributor to morbidity and mortality, with over 17 million deaths occurring annually worldwide. Risk increases in adults over the age of 60, and in part is attributable to inherited genetic makeup.

Cardiovascular disease – which includes coronary heart disease, cerebrovascular disease, peripheral artery disease, and atherosclerosis – is heavily influenced by factors such as insulin resistance, hypertension, dyslipidemia, inflammation, and coagulation properties. Many of these factors can be mitigated by lifestyle changes including smoking cessation, increasing aerobic exercise, and eating a well-balanced diet, which can reduce the risk of catastrophic events such as myocardial infarction, or ischemic and hemorrhagic stroke. However, in some cases, particularly where family history of cardiovascular disease is prevalent, medications or more targeted lifestyle interventions are needed to better manage health outcomes.

Genetic Markers Included in the Behavioral Health Panel

TEST CATEGORIESEFFECTS ON CARDIAC HEALTH
ApoEImpacts management of cholesterol levels and risk of heart attack, stroke, hypertension, and coronary disease
Factor II (Prothrombin)Affects the body’s ability to form blood clots which is tied to the risk of many cardiovascular-related health outcomes
Factor VEnhances body’s coagulability which leads to thromboembolisms
MTHFRContributes to increased levels of homocysteine, a known risk factor for heart disease, atherosclerosis, and peripheral neuropathy
9p21Associated with cellular growth and proliferation in relation to atherosclerosis, arterial stiffness and coronary artery disease
eNOS/NOS3Influences nitric oxide levels leading to risk of endothelial dysfunction, and many subsequent cardiovascular effects
SLCO1B1*5Modulates the body’s ability to metabolize statin medications, which are commonly prescribed to improve cholesterol
AGTKey to maintaining blood pressure, patients who carry this mutation may be at an increased risk of developing hypertension

For Cardiac Pharmacogenetics add
CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5,VKOPC1

Ideal Candidates are Patients with the Following Symptoms or Conditions

  • Treatment-resistant hypertension
  • Poor control over cholesterol levels
  • Personal history of angina, DVT, PE, CHF, MI or CVA
  • Introduction of new statin medications
  • Family history of cardiovascular disease
  • Stroke or heart disease in the young
  • Idiopathic cardiovascular disease

Read Scientific References